Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

This study is testing whether tranexamic acid — a medication that helps control bleeding — can reduce dangerous bleeding events in people with certain blood cancers (myelodysplastic syndromes or acute myeloid leukemia) who have very low platelet counts during chemotherapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) - You are receiving less-intensive chemotherapy (either as first-line treatment or for relapsed/refractory disease) - You have very low platelet counts (platelets at or below 50,000) **You may NOT be eligible if...** - Your medical team believes you are unlikely to survive more than 30 days - You are unable to give informed consent - You have a known allergy to tranexamic acid - You currently have an active blood clot (deep vein thrombosis, pulmonary embolism, etc.) - You have active ischemic heart disease - You have blood in your urine - You have end-stage kidney disease - You are suspected of having a condition called disseminated intravascular coagulation (DIC) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.